Effects of guanabenz on gastrointestinal absorption of hydrochlorothiazide.
The pharmacokinetics of guanabenz (16 mg) and hydrochlorothiazide (25 mg), administered separately and as a fixed-combination tablet (guanabenz 16 mg/hydrochlorothiazide 25 mg), were compared in a randomized three-period crossover study in 24 healthy men. Plasma concentrations were monitored for 48 h after each administration. No statistically significant differences between the two formulations were noted in mean plasma concentrations or the rate and extent of absorption of guanabenz. The relative bioavailability (Fr) of the combination tablet compared with guanabenz alone was 96%; thus the two formulations were bioequivalent with respect to guanabenz. For hydrochlorothiazide, mean plasma concentrations were similar for 3 h after administration but were higher for the combination tablet than for hydrochlorothiazide alone from 4 through 48 h (p less than 0.05). A significant increase in the extent, but not the rate, of absorption of hydrochlorothiazide was observed for the combination tablet (mean Fr, 120%), which is not considered clinically significant. We propose that this increase may have been due to increased systemic availability of hydrochlorothiazide in the presence of guanabenz, an alpha-adrenergic agonist, which may have delayed intestinal transport of hydrochlorothiazide, resulting in enhanced gastrointestinal absorption.
D000328:Adult; D004338:Drug Combinations; D006143:Guanabenz / Q000097:blood / Q000494:pharmacology*; D006146:Guanidines / Q000494:pharmacology*; D006801:Humans; D006852:Hydrochlorothiazide / Q000097:blood / Q000378:metabolism*; D007408:Intestinal Absorption / Q000187:drug effects*; D007700:Kinetics; D008297:Male
D004338:Drug Combinations; D006146:Guanidines; D006852:Hydrochlorothiazide; D006143:Guanabenz